David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).

Lymphoma

Craig H. Moskowitz, MD

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Lymphoma

Jonathon B. Cohen, MD

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

David A. Williams, MD

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Jul

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Hagop M. Kantarjian, MD, on AML: Safety and Efficacy of Guadecitabine

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Jonathon Cohen, MD, on Deferring MCL Treatment

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Virtual Sustained Counseling and Tobacco Treatment Improve Quit Rates for Patients With Cancer in Community Settings

Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC

Digital Check-ins May Improve Outcomes in Patients Undergoing Treatment for Advanced Cancer

How Do Surgical Ovarian Cancer Prevention Strategies Compare for Sexual Function?

ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment